Downstream Processing Featured Articles
-
Roche Receives FDA Clearance For Herpes Simplex Virus Type 1 And 2 Tests
9/4/2012
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IgG Antibody to herpes simplex virus (HSV) types 1 and 2 assays for use on cobas® modular platforms. The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection.
-
Lonza And Sartorius Stedim Biotech Enter Collaboration, Supply And Distribution Agreement In The Field Of Cell Culture Media
12/19/2012
Lonza recently announced together with Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, a long-term global collaboration, supply and distribution agreement in the field of cell culture media.
-
Population Genetics Validates GenomePooling For Cancer
7/31/2012
Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.
-
DSM Announces Patent Grants For Proprietary XD Biomanufacturing Technology
6/19/2012
DSM Biologics focuses on optimizing biopharmaceutical manufacturing through its unique set of technologies. The XD technology is an important building block in DSM’s vision for the future of biopharmaceutical manufacturing.
-
Therapure Announces Opening Of Custom Biologics Manufacturing Wing
4/20/2012
Recently marked the official opening of Therapure Biopharma Inc.’s Custom Biologics Manufacturing Wing, which supports the development and manufacture of innovative medical treatments.
-
Sanofi Pasteur Announces Publication In The Lancet Of World's First Efficacy Results For Its Dengue Vaccine Candidate
9/11/2012
Sanofi Pasteur, the vaccines division of Sanofi, announced recently the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.
-
Untapped Potential Of Protein A To Be Highlighted At BPI Conference
8/19/2015
Pete Gagnon, group manager for downstream processing at the Bioprocessing Technology Institute in Singapore, discusses his upcoming presentation at the 2015 BioProcess International (BPI) Conference. Protein A: the Fine Print, is one of several scheduled during the pre-conference symposia track, Innovation in Process and Product Development Technologies for Biopharmaceutical Development.
-
Abbott To Collaborate With Astellas In CMV Vaccine Trial
9/7/2012
Abbott announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.
-
WHO Member States Make Progress On Noncommunicable Diseases
11/12/2012
The first-ever global monitoring framework to combat several of the world’s biggest killers has been agreed this week by WHO Member States. The framework comprises nine voluntary global targets and 25 indicators to prevent and control diseases such as heart disease, diabetes, cancer, chronic lung disease and other noncommunicable diseases.
-
Refine Technology And Gallus BioPharmaceuticals To Collaborate On Continuous BioManufacturing
1/22/2013
Refine Technology, LLC (Refine), the developer and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, and Gallus BioPharmaceuticals, LLC (Gallus), the industry leading contract bulk biopharmaceuticals manufacturer, today announced a collaboration to optimize continuous cell culture processes.